Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corvus PharmaceuticalsFRA:C17 +0.47%34 EV-to-EBIT is -18.35 as of Aug. 15, 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 368 Biotechnology companies, Corvus Pharmaceuticals ranks worse than 271738.86% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Corvus Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was €850.61 Mil.
Corvus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corvus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's EV-to-EBIT falls into.
Corvus Pharmaceuticals's current Enterprise Value is €900.02 Mil.
Corvus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals (FRA:C17) has a EV-to-EBIT of -18.35 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Corvus Pharmaceuticals and its competitors. According to the industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 368 companies in the Biotechnology industry.
Is Corvus Pharmaceuticals' EV-to-EBIT too high?
Corvus Pharmaceuticals' current EV-to-EBIT is -18.35. Based on the distribution chart, Corvus Pharmaceuticals ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' EV-to-EBIT compare to MGTX and WVE?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 368 companies for EV-to-EBIT. This places Corvus Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.71, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Corvus Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corvus Pharmaceuticals's current EV-to-EBIT is -18.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current EV-to-EBIT of -18.35. The current EV-to-EBIT is -18.35. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current EV-to-EBIT is -18.35 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score
Get the complete analysis for FRA:C17
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C17 has been successfully added to your 
